Phio Pharmaceuticals Corp (PHIO)

1.215
+0.035(+2.97%)
  • Volume:
    111,527
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    1.130 - 1.220

PHIO Overview

Prev. Close
1.18
Day's Range
1.13-1.22
Revenue
-
Open
1.19
52 wk Range
1.13-4.35
EPS
-1.22
Volume
111,527
Market Cap
16.38M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
387,335
P/E Ratio
-
Beta
1.93
1-Year Change
-50.63%
Shares Outstanding
13,534,692
Next Earnings Date
Mar 30, 2022
What is your sentiment on Phio Pharmaceuticals Corp?
or
Vote to see community's results!

Phio Pharmaceuticals Corp Company Profile

Employees
10

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
  • PHIO Sept 16-21 ESMO Abstract Title says it all -> "persistent immunity" & "complete resolution of tumors" (eg 100% tumor elimination & lasting cancer immunity) can't get any better than that. Truly the Market hates PHIO/RXII because of the 'cloud' of 4 R/S 1,000:1 Otherwise PHIO PPS would've exploded. Only other explanation is that the investing public can't read or comprehend the impact of a cure for cancer.
    0
    • Nice move so far today
      0
      • THIS IS GOING TO 6
        0
        • 123 boom
          0
          • Target 10$
            0
            • $5.75
              0
              • Why such thebig fump
                0
            • going up
              0
              • is this going to keep going up or dip
                0
                • did they already have earnings call?
                  0
                  • will up
                    1
                    • you believe so Ammar
                      1
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.